Hyderabad, Apr 15 (TNT): MSN Laboratories on Wednesday announced the launch of ‘SEMABEST’, its semaglutide brand, in the Indian market for the treatment of Type 2 Diabetes, following approval from the Central Drugs Standard Control Organisation (CDSCO).
In a release, the Hyderabad based pharma company said the therapy, available as a pre-filled pen for subcutaneous administration, is priced nearly 50 per cent lower than the innovator drug, aimed at improving affordability and access for patients.
SEMABEST has demonstrated bioequivalence to the reference drug, with Phase III clinical studies showing comparable reduction in HbA1c levels and similar outcomes in fasting plasma glucose (FPG), postprandial glucose (PPG) and weight loss.
The product also showed a comparable safety profile.
The launch follows the recent patent expiry of semaglutide, with multiple players entering the segment.
The company said its product is backed by strong backward integration, including in-house USDMF-grade API and formulation, along with a pen device manufactured in India in line with global standards.
India has an estimated 90 million people living with diabetes, many of whom remain undiagnosed or inadequately managed, increasing the risk of complications such as cardiovascular disease, kidney failure and vision impairment.
The launch marks a step towards expanding access to advanced metabolic therapies, supported by its experience in complex peptide development and global manufacturing capabilities, the release said.
Founder and CMD Dr MSN Reddy said the launch marks a key step in expanding access to next-generation metabolic therapies, while senior officials highlighted the company’s experience in complex peptide development and its global regulatory footprint.
Established in 2003, MSN Pharmaceuticals Group operates 25 manufacturing facilities across India and the United States, with a portfolio spanning over 550 APIs and 400 finished dosage forms across more than 35 therapeutic areas, serving patients in over 100 countries.
TNT TS
Leave a Reply